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An HLA-DR3 association with membranous nephropathy was described in 
1979 and additional evidence for a genetic component to membranous 
nephropathy was suggested in 1984 in reports of familial membranous 
nephropathy (1,2). In 2009, a pathogenic autoantibody was identified against 
the phospholipase A2 receptor 1. 
Here, we discuss the genetic studies that have proven the association of 
human leucocyte antigen class II and phospholipase A2 receptor 1 variants 
and disease in membranous nephropathy. The common variants in 
phospholipase A2 receptor 1 form a haplotype which is associated with 
disease incidence. The combination of the variants in both genes significantly 
increases the risk of disease by 78.5 fold (3). There are important genetic 
ethnic differences in membranous nephropathy. Disease outcome is difficult 
to predict and attempts to correlate the genetic association to outcome have 
so far not been helpful in a reproducible manner. The role of genetic variants 
may not only extend beyond risk of disease development, but can also help 
understand the underlying molecular biology of the phospholipase A2 receptor 
1 and its resultant pathogenicity. The genetic variants identified thus far have 
an association with disease and could therefore become useful biomarkers to 
stratify disease risk, as well as possibly identifying novel drug targets in the 
near future. 
  

































































Membranous nephropathy (MN) is a kidney specific autoimmune disease with 
an incidence of ten per million per year (4). It is the leading cause of nephrotic 
syndrome in European adults and progresses to end-stage renal disease 
(ESRD) in 30-40% of cases (5). Unlike many other autoimmune disorders, 
males are more often affected. Approximately 25% of patients have a 
secondary form of MN, which is diagnosed when an alternative identifiable 
underlying clinical condition is present. For example systemic lupus 
erythematosus, malignancy, medication or viral infections (5). The remaining 
75% of patients have no apparent cause and are termed ‘primary’ or 
idiopathic membranous nephropathy (IMN) (6). IMN is caused by in situ 
binding of circulating antibodies to a podocytic antigen. The phospholipase A2 
receptor 1 and thrombospondin type-1 domain-containing 7a are the major 
target antigens involved in the pathogenesis of IMN (7,8). Sub-epithelial 
immunoglobulin rich deposits demonstrated by electron microscopy are 
pathognomonic in MN (9), constituting a definitive phenotype. While IMN does 
not show simple Mendelian inheritance, the role of underlying genetic factors 
has been confirmed in recent studies. 
 
Discovery of autoantigens 
The first autoantigen described in a rare case of antenatal MN was neutral 
endopeptidase (NEP), in 2002 (10). The gene encoding NEP is 
metallomembrane endopeptidase. Truncated mutations were discovered in 
maternal DNA so the mother did not express NEP protein. When foetal NEP 
(paternal protein) was encountered during pregnancy, anti-NEP antibodies 
developed (with no consequence to the mother) which crossed the placenta to 
cause neonatal MN (10,11).  































































The discovery of circulating antibodies to the autoantigen phospholipase A2 
receptor 1 (PLA2R1) revolutionised our understanding of IMN as an 
autoimmune disease (7). With Western blots and mass spectrometry the 
antibody was detected in serum from 26 out of 37 patients (70%) (7). This has 
been confirmed in subsequent studies and proven to be specific to IMN and 
implicated in disease progression and outcome (12,13). 
Most recently, combined immunologic and proteomic approaches identified 
thrombospondin type-1 domain-containing 7A (THSD7A) as another target 
autoantigen in MN (8). THSD7A antibodies are found in approximately 2-3% 
of MN patients. THSD7A like PLA2R1 is a heavily glycosylated, multi-domain 
transmembrane receptor located on the podocyte membrane. THSD7A 
resembles some of the PLA2R1 immunological characteristics and 
autoantibody findings correlate with glomerular staining of the antigen. It is not 
understood why autoantibodies develop however, in some THSD7A 
associated cases the development of antibodies may be linked to malignant 
tumours (14,15). Interestingly, dual positivity to both PLA2R1 and THSD7A is 
extremely rare with only 2 cases identified on biopsy staining (16). 
 
Familial clustering of Membranous Nephropathy 
Whilst all available data points towards a strong genetic component, IMN 
appears not to be inherited in a simple Mendelian fashion. In 1984 the first 
case of identical twins developing IMN was published (17), and to date 
sixteen families have been reported to have familial IMN (3,18,17,19–24), 
suggesting strong genetic contribution. However, several sets of monozygotic 
twins with IMN had different phenotypes with a different age of onset and 
progression of disease (17,22). This suggests an environmental contribution 
to disease, which is not yet well established. 































































There is a strong male preponderance in IMN (25) unlike other autoimmune 
diseases (26). An X-linked recessive pattern of inheritance was suggested 
based on the clustering of disease between non-identical brothers (17–19,21). 
Autosomal inheritance was also apparent in other families with male-to-male 
transmission (20,24) and affected members of both genders (18,23). Further 
support for the theory of an underlying genetic mechanism was provided by 
two brothers with a rare syndromic form of IMN (19). These brothers had both 
IMN and deafness but no linked HLA alleles (19). To date the involvement of 
antibodies against phospholipase A2 receptor 1 (aPLA2R1ab) in cases of 
familial MN are unknown. 
Two studies of paediatric primary MN report much lower positivity for PLA2R1 
staining of immune complexes on biopsy at 6% and 45% compared to adult 
studies at 70-80% (27,28). As yet the genetic background to paediatric MN 
has not been confirmed. 
 
Concept of genome-wide association studies and confirmation of 
genetic association 
 
The biggest breakthrough in the contribution of genetic factors in IMN so far 
was with three genome-wide association studies (GWAS) published in 2011 
(3). GWAS works with the hypothesis that the phenotype is associated with 
variations in a subset of several genes. These variations will be demarked by 
haplotypes / alleles that display frequency differences in the cases and 
controls. GWAS examine all chromosomes and its simplest form compares 
allele frequencies of given variations in cases to allele frequencies of controls 
(basic allele test). GWAS most often use common single nucleotide 
polymorphisms (SNP), which are defined by an allele frequency in a given 
population of > 5%. The tenet is that any given disease, as long as there is no 































































heterogeneity, will show a difference in the frequency of genetic variation 
within disease-associated genomic regions in comparison to unaffected 
controls. Thus, SNPs utilized as genetic markers, identify a chromosomal 
location of interest associated with disease. If the phenotype is clearly 
described and unique then GWAS can be powerful for discovery of associated 
alleles even with few cases (29,30). The first ever GWAS published in 
macular degeneration utilised 96 cases and 50 controls only (29). Of all SNPs 
genotyped 105,980 were analysed and an intronic and common variant in the 
complement factor H gene that increased the likelihood of macular 
degeneration by a factor of 7.4 was discovered (29). This is contrary to the 
opinion (misconception) often presented in public that GWAS always need 
thousands or tens of thousands of samples to be able to identify genetic 
causes. When a phenotype is complex (i.e. hypertension, kidney failure), then 
indeed many more samples are needed to be able to identify regions of 
interest, i.e. associated alleles. 
 
Genome-wide association studies in membranous nephropathy 
The GWAS published in 2011 investigated European populations with renal 
biopsy proven IMN (3).  Three independent GWAS were performed, using 75 
French European cases, 146 Dutch European cases and 335 British 
European cases. Despite the small number of cases even in the smallest 
cohort (French), a significant association in 3 SNPs in an HLA-DQA1 allele on 
chromosome 6 was found. The 146 Dutch cases demonstrated a significant 
allelic association of 191 SNPs in HLA-DQA1. Additionally, 6 SNPs located 
within the PLA2R1 gene on chromosome 2 were associated with IMN, the 
strongest being SNP rs4664308. Finally, the British study found a significant 
association with 144 SNPs in the HLA-DQA1 allele and 2 SNPs in the 
PLA2R1 allele. Combining then the three cohorts in a meta-analysis with a 
total case population of 556 further strengthened the association of IMN with 































































20 SNPs in HLA-DQA1 and 13 SNPs in PLA2R1. The effect size of the risk 
SNPs was examined, even in a heterozygous state of the risk allele the odds 
ratio was increased in both HLA-DQA1 and PLA2R1. The strongest 
association was with the HLA-DQA1 region, (the most significantly associated 
SNP being rs2187668) (3). In a homozygous state of the HLA-DQA1 risk 
allele the odds ratio of IMN was 20.2 (3). The odds ratio in a homozygous 
state for PLA2R1 was 4.2 (3). Combining these two risk alleles further 
increased the risk of IMN to an odds ratio of 78.5 (3). This association was 
very robust for such a modest cohort (31), which is unusual for a GWAS (18). 
Also, no association was found with immunoglobulin G chains that were 




The SNP coverage of these initial GWAS is low compared to the coverage 
available with more modern technology, particularly of the HLA alleles (34,35). 
To further assess the strength of the SNP associations that were found in the 
British study an imputation study was performed (36). Imputation is a method 
to increase the statistical power of association studies and potentially identify 
additional associated alleles (37,38). This technique is based on knowledge 
about short stretches of shared haplotypes to provide information and predict 
untyped alleles (39). Imputation takes advantage of haplotype composition to 
match known SNPs to other SNPs that are in linkage disequilibrium with one 
another. In this way, it was possible to impute and examine 8.9 million SNPs 
in the British cohort. The strongest signals remained in HLA-DQA1 and 
PLA2R1, and no additional loci were found as independent risk factors. The 
PLA2R1 signal was somewhat weaker and HLA-DQA1 somewhat stronger 
than originally described, with homozygous risk alleles at both loci the 































































combined odds ratio was greater at 79.4 (36). In addition, imputation of 
classical HLA alleles was performed, with the DRB1*0301-DQA1*0501-
DQB1*0201 haplotype showing the strongest association but providing little 
information beyond the lead SNP in HLA-DQA1. Sub-group analyses were 
undertaken and there was no significant gender specific genetic difference 
and no additional loci were found on the X chromosome (36), which may have 
been unexpected given the unusual strong male preponderance in IMN, but 
statistical power for these analyses was limited. The HLA region was 
analysed in much more detail and this demonstrated a several hundred 
kilobase pair linkage disequilibrium around HLA-DQA1 as well as other HLA 
class II genes (36). 
 
M-type phospholipase A2 receptor 1 
To investigate whether specific variants within the PLA2R1 gene are causing 
this previously mentioned strong genetic association, sequencing of the 30 
PLA2R1 coding exons was performed. This was also an ethnically 
homogenous group, all 95 affected patients were white Europeans and only 
45% had circulating aPLA2R1ab (40). All exons and splice sites of PLA2R1 
were sequenced by Sanger sequencing and all observed variants including 
rare variants (minor allele frequency <1%) were analysed. To our initial 
surprise, no rare genetic variants causing a conformational change in PLA2R1 
structure were found. Of the variants found 6 were common and 3 in splice 
sites (exon-intron boundaries). One of these non-synonymous (causing amino 
acid alteration) common variants (i.e. M292V) encodes an amino acid located 
within CTLD1 but this is far removed from the immunodominant epitope in the 
N-terminal cys-rich domain and unlikely to have a contributory role in the 
pathogenesis of IMN (40,41). One reason for the lack of exonic, i.e. coding, 
differences may be that the true causal variant(s) lie(s) in the regulatory, i.e. 































































intergenic or intronic regions of the gene. For this to be examined, sequencing 
of the whole genomic region would need to be done. A second reason for the 
lack of significant results was that only 45% of the cohort had detectable 
aPLA2R1ab. The remaining patients were aPLA2R1ab negative, and we now 
know that the association is strongest in aPLA2R1ab positive patients.  
It is therefore most interesting to note that despite IMN being a rare disease 
the variants found in PLA2R1 were common. An explanation for this would be 
that the common variants recognised together create a rare haplotype (40). 
Additionally, an interaction between the PLA2R1 variants and the HLA-DQA1 
haplotype in individuals predisposed to developing IMN might be infrequent in 
causing autoimmunity and may therefore account for the rarity of disease and 
suggest a mechanism for how IMN develops (42). Genotyping of hundreds of 
thousands of individuals will provide an answer to whether there is a unique 
genetic fingerprint of individuals developing IMN and what proportion of 
individuals having this genetic fingerprint actually present with IMN (i.e. show 
penetrance). 
 
Antibody and gene interplay 
The presence of circulating antibodies against PLA2R1 and THSD7A is 
variable between patients and throughout the different stages of disease (43). 
During active nephrosis and disease these levels tend to be high and 
remission is predated by reducing antibody titres (43). Serologically antibody 
negative MN patients may have glomerular PLA2R1 positivity (12). The 
underlying pathological mechanism in tissue or serological PLA2R1 positivity 
is the same and they represent a spectrum of the same disease. A hypothesis 
is these patients have the same genetic PLA2R1 risk variants yet are 
demonstrating incomplete penetrance of disease manifestation. Studies were 
undertaken to elucidate the association of genetic variants and circulating 































































antibodies as the antibody titres have been associated with severity of 
disease and long term outcome (13).  
PLA2R1 risk alleles are positively correlated with positivity of the pathogenic 
aPLA2R1ab (44). When patients were divided into low- or high-risk PLA2R1 
genotypes, only 4% of those with the low-risk genotype had detectable 
aPLA2R1ab compared to 76% of those with the high-risk genotype (44). This 
association was further strengthened for the detection of aPLA2R1ab after 
combination with the low- or high-risk HLA-DQA1 genotypes with 0% versus 
73% respectively (44). A larger study compared glomerular PLA2R1 antibody 
staining (positivity) to negative patients and found the PLA2R1 association 
only in patients with PLA2R1 positivity. In PLA2R1 negative patients compared 
to controls there was no association with PLA2R1 SNPs (45). 
This is relevant as increased aPLA2R1ab correlates with clinical progression 
of disease; with higher titres associated with ESRD at five years and lower 
rates of spontaneous remission (13). In an Indian cohort, however, there was 
no significant association between aPLA2R1ab status and PLA2R1 SNPs. 
Instead there was an association of the HLA-DQA1 risk allele with 
aPLA2R1ab positivity (46). This was subsequently replicated in a European 
cohort and the presence of the risk alleles in either a heterozygous or 
homozygous state in HLA-DQA1 and -DQB1 was significantly associated with 
higher circulating aPLA2R1ab (13). Neither the SNPs in intron 1 or exon 5 in 
HLA-DQA1 alone had an effect on aPLA2R1ab titres (13). Two recent 
Chinese studies demonstrated the strong HLA association with aPLA2R1ab 
positivity (47,48). One had an association with HLA-DRB1 and the other HLA-
DRB3 both of which share a haplotype so may represent a common 
mechanism in Chinese patients (47–49). The risk alleles in PLA2R1 are said 
to be present in patients with systemic lupus erythematosus (SMN) albeit with 



































































Our findings from the first IMN GWAS (3) have been replicated in other 
studies, however different techniques have been used. These studies use a 
candidate gene approach whereby a specific variant alone is genotyped (52). 
These SNPs are chosen as the candidate gene based on prior knowledge 
about PLA2R1 or previously described SNPs (52,53). This is a major limitation 
of the candidate gene approach; they can only confirm or refute an 
association with a variant and cannot detect new associations (52,53). 
Another limitation is findings are often not replicated in subsequent 
independent studies rendering the results potentially unreliable (52,53). Table 
1 provides a summary of genotyping studies to date in MN. 
In MN, the first study utilising the candidate gene approach was a small 
Spanish cohort of 89 patients, where only a single SNP in both the HLA-
DQA1 and PLA2R1 genes was investigated (54). This study too found the 
same association in both alleles in their cohort, with an added effect of 
homozygous risk alleles in both genes increasing the odds ratio of IMN to 7.3 
(54). As these studies were performed in European populations it was of 
interest to investigate if these associations held true in other ethnicities. 
In a cohort of 114 Indian patients the same risk alleles were identified as by 
Stanescu et al. (46). The strongest association was with the homozygous 
genotype in the HLA-DQA1 SNP rs2187668. Three SNPs were associated 
within PLA2R1, one of which was the same SNP described in the GWAS (3), 
rs4664308 with the AA risk genotype (46). The risk of IMN was increased by 































































58.4 with all four risk alleles in HLA-DQA1 and PLA2R1 (46). This is a strong 
association with a small sample size.  
The only study undertaken in African-Americans so far examined 243 African-
American and 467 European cases of IMN (45). Targeted sequencing of 
candidate genes using conventional polymerase chain reaction was 
performed, with genotyping of 6 PLA2R1 SNPs and a single SNP in the HLA-
DQA1 region (45). Further, they differentiated between patients who had 
PLA2R1 positivity on renal biopsy (using immunofluorescence) (115 African-
American cases) and those who did not (128 African-American cases) (45). 
No association was found in African-Americans with the HLA-DQA1 SNP 
rs2187668, suggesting that this SNP is tagging the causal variant(s) in 
individuals of European and East Asian ancestry but not in African Americans. 
In the European sub-group analysis however, the strong association was 
present with HLA-DQA1 (45). Further the PLA2R1 signal was associated with 
glomerular PLA2R1 positivity in the African-American cohort but not in 
PLA2R1 negative patients (45). The strength of this association was lower 
than that found in Europeans, with the strongest association in Europeans 
with detectable PLA2R1 (45).  
Chinese patients demonstrated a similar association with PLA2R1 risk alleles 
increasing the risk of IMN but without any effect on outcomes and response to 
treatment (55). Liu et al. analysed 2 SNPs in 129 Chinese IMN patients (55). 
The risk allele increased the rates of IMN (55). There was no difference in the 
different genotypes relating to progression to ESRD, though the patient 
numbers were too small to identify such a difference. A heterozygous state for 
the risk allele in the exonic PLA2R1 region conferred a lower success rate of 
achieving remission (55). A larger study including 1112 Chinese patients with 
IMN genotyped 3 SNPs in PLA2R1 and 3 SNPs in HLA genes and found that 
both were associated with IMN (44). Interestingly, in the Chinese population 































































the association with HLA-DQA1 was lower than in Europeans, and there was 
no association with HLA Class II alleles apart from HLA-DOB or -DQB2 (44). 
A study of 261 IMN Chinese patients has linked HLA-DRB1*1501 most 
significantly with IMN (47). After correction for HLA-DRB1*0301, the HLA-
DQA1 association was diminished as these two loci are in strong linkage 
disequilibrium with one another (47). The additive effect of homozygous risk 
alleles in HLA-DQA1 and PLA2R1 increased the odds ratio of IMN to 11.13 
which is considerably lower than that found in the European studies (3,44). 
However, with the newly discovered association of HLA-DRB1 and PLA2R1 
the odds ratio is considerably higher at 32.4 in the Chinese population (47). 
Another Chinese study in patients phenotyped by PLA2R1 positivity 
demonstrated a stronger association with HLA-DRB3*0202 and HLA-
DRB1*1501 with odds ratios of 24.9 and 17.7 respectively (48). Both studies 
have identified the same allele in HLA-DRB1*1501 which may truly represent 
the causative allele in Chinese patients. Difficulties arise with analysis of such 
data as the allele frequencies vary between ethnic groups (56). The Chinese 
are genetically heterogeneous and within a control population there were 
different minor allele frequencies in HLA-DQA1 and PLA2R1 dependent on 
their geographical location (56).  
A study of 4 SNPs in PLA2R1 in 199 Korean patients also confirmed an 
association of disease with rs35771982 and rs3828323 (different to the 
Stanescu et al. SNPs (3,57). Patients with SMN had the same genotype as 
controls (57). 
Finally, a Japanese study performed genotyping of 15 SNPs in the PLA2R1 
gene and 6 HLA genes - A, B, C, DRB1, DQB1 and DPB1 (58). The discovery 
sample had 53 patients, and the replication study 130 (58). After corrections 
for multiple testing and correlation in the replication study 4 SNPs in PLA2R1 
were associated with IMN, 2 of which were intronic (58). None of the class I 































































HLA genes (A, B or C) were significantly associated with IMN, however HLA-
DRB1*15:01 was the most strongly associated with an odds ratio of 2.85 
followed by HLA-DQB1, odds ratio 2.6. These odd ratios increased in the 
replication study and then subsequently in the combined analysis to 3.09 and 
3.1 respectively (58). Interactions between the HLA and PLA2R1 homozygous 
risk alleles further increased the risk of developing IMN, with the largest odds 
ratio of 17.53 in the HLA-DRB1*15:01 – DQB1*06:02 and rs2715928 PLA2R1 
combination. Whilst these interactions are statistically significant they are still 
considerably lower than the strength of interactions found in the European 
GWAS (3). The differences may be due to sample size differences or because 
HLA-DQA1, which is a larger contributor to the cumulative risk in the 
European study, was not genotyped in this Japanese study, or because of 
differences in linkage disequilibrium with the causal variant across different 
ethnic groups. 
 
Functional effect of genes 
The underlying genetic risk alleles that have been identified to date are 
different between individual studies but universally there is an association of 
IMN with the human genes encoding leucocyte class II antigens and PLA2R1. 
Functional studies to ascertain how these genetic variants increase the risk 
for disease development are required. It is also possible that the previously 
identified risk alleles do not affect disease onset but instead disease severity 
(42).  
It is unclear how the genetic risk alleles of class II HLA (e.g. DQA1) and 
PLA2R are translated through the pathophysiological disease mechanism, but 
antigen presentation to T cells to initiate T cell help for aPLA2R1ab production 
is one possibility. These risk alleles encode protein receptors which interact 































































during antigen presentation to stimulate T cells. In this situation, PLA2R1 
protein, processed in macrophage/dendritic cells is displayed on the cell 
surface as PLA2R1 peptides bound to the class II receptor (DQA1) groove. 
The genetics of DQA1 will shape the amino acid structure of its receptor 
groove thus defining and restricting the possible 15mer peptide sequences 
available from PLA2R1 that will fit the groove. The genetics of PLA2R1 may 
control the possible enzyme fragmentation pattern of PLA2R1 by: 
a) change in amino acid either creating or destroying an enzyme cut site 
b) change in splice sites controlling the protein species available for 
fragmentation 
c) level of transcript leading to higher levels of peptide 
As yet these T cell peptides (the PLA2R1 peptides presented on DQA1) have 
not been described experimentally but studies are in progress. A recent study 
has predicted possible T cell epitopes in PLA2R1 and attempted to model the 
interaction with known class II risk alleles (47). It is important to emphasise 
that DQA1 may not be the causal allele, particularly in non-European 
ethnicities (47,48).  
To elucidate the HLA causal alleles further larger multi-ethnic GWAS 
combined with larger-scale HLA sequencing and fine-mapping studies are 
necessary. It is vital to do this before modelling their functional effects 
however, it would be useful to have transcriptomic and proteomic studies to 
ascertain if PLA2R expression is modified and if this is due to an increase or 
decrease in transcriptional or post-transcriptional events.  
 
Remission status 
A comparison of 23 spontaneously remitting to 55 non-remitting IMN patients 
found no difference in genetic variants in HLA-DQA1 or PLA2R1 (54). In 































































contrast, Liu et al. reported an association between lower rates of remission 
after treatment and the PLA2R1 SNPs rs6757188 (CT genotype) and 
rs35771982 (CG genotype) (55).  
 
Response to treatment 
Patients with the risk genotypes in HLA-DQA1 and PLA2R1 respond to 
immunosuppression, though the odds ratio is low at only 0.12 (54). The total 
number of patients assessed was small with 27 responders and 28 non-
responders (54). After adjustment for baseline proteinuria the predictive value 
of risk genotype increased (54). Analysis of 2 different PLA2R1 SNPs 
revealed no difference between the outcomes of patients treated either 
conservatively or with immunosuppression (55).  
 
Decline in renal function 
The high risk alleles (AA genotype) in HLA-DQA1, despite being strongly 
associated with IMN, are potentially protective against declining renal function 
(54). High risk genotype patients had a longer time to doubling of their serum 
creatinine of 16.3 years compared to 13 years, though this was a small 
subgroup of only 83 patients (54). No association was found in the 8 
Japanese patients that had a 50% increase in their serum creatinine with 
HLA-DRB1 and -DQB1 over an 11 year period, nor with patient survival (58). 
The association with PLA2R1 risk alleles and declining renal function has 
been investigated in different ethnicities and no association was found 
(54,57). In addition there was no association with ESRD or death (55). As yet 
there has been no conclusive evidence associating genetic variants to 
remission status, response to treatment or a decline in renal function. These 
factors are difficult to determine as studies are often done in retrospective 































































cohorts where confounders such as immunosuppression or disease severity 
have a significant effect on the outcomes. Decline in renal function is 
multifactorial and is related to blood pressure control, severity of proteinuria, 
renal function at disease onset, age and gender amongst others. These 
factors themselves are likely to be independent risk factors which is why 
studies to date have not been significant. It may be argued that these factors 
are caused or influenced by genetics thereby further complicating the 
potential genetic risk profile with IMN. 
 
Response to treatment 
There has been an exponential increase in our understanding of IMN since 
2009, when PLA2R1 was identified as the most significant pathogenic 
autoantigen in IMN. IMN therefore may occur when three independent risk 
factors combine: unique polymorphisms in PLA2R1, the HLA-DQA1 region 
and environmental factors. There are ethnic specific differences in these 
alleles and the potential that risk alleles may contribute in predicting disease 
outcomes. The complex pathomechanisms of disease development highlight 
some of the potential problems in analysing and predicting the risk for disease 
progression. The genetic variants may alter the expression or function of the 
target antigens and enable autoantibody formation. While no rare variants (i.e. 
mutations) were found in the coding region of PLA2R1 the role of intronic 
variants needs to be investigated given their large regulatory role. As shown 
before, non-coding SNPs (i.e. intergenic or intronic genetic variations) are 
associated with ESRD (59) and other autoimmune conditions (60).  
Whole genome sequencing is becoming more affordable and faster and may 
help illuminate the true role of intergenic and intronic genetic variants in IMN. 
The genomic studies could be augmented with epigenomic, transcriptomic 
and proteomic studies to ascertain the functional effect of gene variants. The 































































regulatory regions that control autoantibody production such as transcription 
factors or micro RNA could be altered by the identified risk SNPs in a 
mechanism analogous to psoriasis (31). If upstream and downstream 
regulatory region variants were found these would be potential therapeutic 
drug targets, possibly preventing the deleterious effects of current 
immunotherapy. Given the large odds ratio with joint homozygosity, 
genotyping could be utilised to stratify disease risk and outcomes. The utility 
of genetic profiling in IMN could prove to be vital for non-invasive screening or 
risk stratification (18,31). The tools (aPLA2R1ab) available to us are of 
assistance but by understanding the genetics we may be able to explain why 
the autoantibodies develop in the first instance (18). Current studies have 
been limited by small sample size and so there may be a lack of appreciation 
of potential other associations. Expanding the horizons further, there may 
even be a role for ascertaining epidemiologic risk for IMN with risk alleles and 
seeing if people in the general population have a genetic predisposition to 
disease (18). There may be an indirect interaction between genetics and 
disease, such as molecular mimicry whereby a microbe or environmental 
antigen resembles a PLA2R1 variant and causes autoimmunity in patients 
carrying the HLA-DQA1 risk alleles (42). The reported homology of part of the 
major epitope sequence in PLA2R1 with a clostridial carbopeptidase enzyme 
illustrates how antibodies raised during infection may potentially cross react 
with an autoantigen (41). Normal control populations without IMN but with the 
risk alleles will be the most useful in identifying the triggers or environmental 
factors that contribute to eventual disease acquisition which may further our 
understanding of this complex genetically predisposed disease. 
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Study authors SNP Ethnicity (n) Serum ab positivity 
Glomerular PLA2R1 
positivity Allele Odds  p-value (n) Allele 
        (n) (n) frequency ratio 
  
frequency 
        
       Liu et al. (2010)   Taiwanese Chinese 129 unknown unknown       106   
  PLA2R1 - rs6757188         67.80% 1.18 0.4   64.20% 
  PLA2R1 - rs35771982         84.10% 1.9 0.005   73.60% 
                      
Kim et al. (2010)   Korean 199 unknown unknown       356   
  PLA2R1 - rs35771982         73.60% 2.6 <0.001   68.90% 
  PLA2R1 - rs3828323         73.90% 1.35 0.09   71% 
                      
Stanescu et al. (2011)                     
   French study   French European 75 unknown unknown       157   
  HLA-DQA1 rs2187668         31.30% 4.48 1.80E-09   9.20% 
  PLA2R1 rs4664308         23.30% 1.87 5.10E-03   36.30% 
   Dutch study   Dutch European 146 unknown unknown       1832   
  HLA-DQA1 rs2187668         37% 3.76 5.60E-27   13.50% 
  PLA2R1 rs4664308         26% 2.27 1.00E-09   44.40% 
   British study   British European 335 unknown unknown       349   
  HLA-DQA1 rs2187668         41.90% 5.33 5.20E-36   11.90% 
  PLA2R1 rs4664308         25.30% 2.1 2.10E-10   41.60% 
   Joint study   European 556 unknown unknown       2338   
  HLA-DQA1 rs2187668         39.20% 4.32 8.00E-93   13% 
  PLA2R1 rs4664308         25.20% 2.28 8.60E-29   43.40% 
                      
Lv et al. (2013)   Chinese Han 1112 36 of 71 patients (subgroup) unknown       1020   
  PLA2R1 - rs35771982         15.50% 2.36 1.90E-30   30.10% 
  PLA2R1 - rs3749117         15.60% 2.32 2.23E-29   30% 
  PLA2R1 - rs4664308         84.50% 2.35 4.17E-30   70% 
  HLA-DQA1 - rs2187668         12.10% 2.42 1.11E-14   5.40% 
                      
Saeed et al. (2014)                     
  HLA-DQA1 - rs2187668 Caucasian   only ab positive analysed --> 280 44% 3.03 1.30E-33 337 20% 
    African   only ab positive analysed --> 115 20% 2.17 9.84E-07 218 10% 
    All   only ab positive analysed --> 530 35% 2.27 1.39E-10 556 16% 
  PLA2R1 - rs35771982 Caucasian 813 only ab positive analysed --> 280 26% 1.98 1.44E-14 337 49% 
    African 466 only ab positive analysed --> 115 7% 1.74 0.03 218 17% 
    All 1512 only ab positive analysed --> 530 21% 1.53 1.39E-10 556 36% 
                      
Bullich et al. (2014)   Spanish European 89 unknown unknown       286   
  HLA-DQA1 - rs2187668         29% 3.7 <0.001   14% 
  PLA2R1 - rs4664308         26% 2 0.05   36% 
                      
Ramachandran et al. 
(2015)   South Asian - Indian 114 76 86           






























































      94 either either       95   
  HLA-DQA1 - rs2187668   114     39.50% 4.73 <0.0001 95 12.20% 
        only ab positive analysed --> 94   5.36 <0.0001 95   
  PLA2R1 - rs3749119     only ab positive analysed --> 94 85.20% unknown 9.40E-05 95 69% 
  PLA2R1 - rs35771982     only ab positive analysed --> 94   3.17 <0.0001 95   
  PLA2R1 - rs4664308     only ab positive analysed --> 94   3.1 0.0003 95   
                      
Thiri et al. (2016)   Japanese                 
   Discovery analysis     53 unknown unknown       419   
  PLA2R1 - rs1511223         83% 2.24 3.08E-03   68.60% 
  PLA2R1 - rs35771982         82.10% 3.58 2.99E-07   56.10% 
  PLA2R1 - rs2203053         52.90% 1.58 6.17E-03   41.50% 
  PLA2R1 - rs10196882         28.80% 2.25 4.41E-03   15.30% 
  PLA2R1 - rs16844706         43.70% 1.55 8.27E-03   33.40% 
  PLA2R1 - rs877635         49.10% 3.07 1.10E-06   23.90% 
  PLA2R1 - rs2715928         67.30% 2.12 5.84E-04   49.40% 
  PLA2R1 - rs16844715         72.10% 3.12 6.21E-07   45.30% 
  PLA2R1 - rs3749119         15.70% 4.02 7.02E-08   57.20% 
  HLA-A*3303         3.80% 0.39 3.00E-02   9.10% 
  HLA-B*0702         0.90% 0.13 6.33E-03   6.80% 
  HLA-B*3501         14.20% 1.9 3.00E-02   8.00% 
  HLA-B*4403         2.80% 0.33 2.00E-02   8.10% 
  HLA-Cw*0102         8.50% 0.47 1.00E-02   16.60% 
  HLA-Cw*0704         4.70% 5.89 5.79E-03   0.80% 
  HLA-Cw*1403         2.80% 0.33 2.00E-02   8.20% 
  HLA-DRB1*0101         1.90%   0.02   6.80% 
  HLA-DRB1*0405         6.60%   0.01   14.60% 
  HLA-DRB1*1302         2.80%   0.03   7.80% 
  HLA-DRB1*1501         19.80%   7.72E-05   8.00% 
  HLA-DRB1*1602         2.80%   0.01   0.20% 
  HLA-DQB1*0401         6.60%   0.01   14.60% 
  HLA-DQB1*0501         2.80%   0.03   7.50% 
  HLA-DQB1*0602         17.90%   5.12E-04   7.80% 
  HLA-DQB1*0604         2.80%   0.03   7.50% 
  HLA-DQB1*0401         1.90%   0.04   6.10% 
                      
   Replication analysis   Japanese 130 unknown unknown       386   
  PLA2R1 - rs1511223         79.30% 1.57 1.57E-01   70.90% 
  PLA2R1 - rs35771982         78.70% 2.57 1.88E-08   59.10% 
  PLA2R1 - rs10196882         20.80% 1.41 ns   15.70% 
  PLA2R1 - rs877635         27.20% 1.03 ns   26.50% 
  PLA2R1 - rs2715928         71.70% 2.36 4.56E-07   51.70% 
  PLA2R1 - rs16844715         66.10% 2.23 5.16E-07   46.70% 
  PLA2R1 - rs3749119         79.20% 2.61 1.63E-08   59.30% 
  HLA-DRB1*1501         20.20% 3.36 4.97E-08   7% 
  HLA-DQB1*0602         19.80% 3.56 7.20E-09   6.50% 






























































                      
Le et al. (2017)                     
   Discovery analysis   Chinese - Nanjing region 99 Dual positivity all  (single positivity excluded)       100   
  HLA-DRB1*1501         81.80% 16.93 2.75E-15   21% 
  HLA-DRB3*0202         60.60% 3.96 5.73E-06   28% 
   Replication analysis   Chinese - Nanjing region 293 Dual positivity all  (single positivity excluded)       285   
  HLA-DRB1*1501           8.32 3.44E-28     
  HLA-DRB3*0202           7.72 2.28E-27     
   Combined analysis   Chinese - Nanjing region 392 Dual positivity all  (single positivity excluded)       385   
  HLA-DRB1*1501         72.20% 24.9 2.30E-35   21% 
  HLA-DRB3*0202         69.90% 17.7 8.00E-29   26.50% 
                      
Cui et al. (2017)                     
  HLA-DRB1*1501 Chinese Han 261 66.3% positive Not checked 37.55% 4.65 <0.001 599 14.69% 
  HLA-DRB1*0301         12.07% 3.96 <0.001   3.84% 
                      
 
Table 1: Summary of genotyping studies of the HLA region and PLA2R1 in IMN arranged by date of publication. 
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An HLA-DR3 association with membranous nephropathy was described in 
1979 and additional evidence for a genetic component to membranous 
nephropathy was suggested in 1984 in reports of familial membranous 
nephropathy (1,2). In 2009, a pathogenic autoantibody was identified against 
the phospholipase A2 receptor 1. 
Here, we discuss the genetic studies that have proven the association of 
human leucocyte antigen class II and phospholipase A2 receptor 1 variants 
and disease in membranous nephropathy. The common variants in 
phospholipase A2 receptor 1 form a haplotype which is associated with 
disease incidence. The combination of the variants in both genes significantly 
increases the risk of disease by 78.5 fold (3). There are important genetic 
ethnic differences in membranous nephropathy. Disease outcome is difficult 
to predict and attempts to correlate the genetic association to outcome have 
so far not been helpful in a reproducible manner. The role of genetic variants 
may not only extend beyond risk of disease development, but can also help 
understand the underlying molecular biology of the phospholipase A2 receptor 
1 and its resultant pathogenicity. The genetic variants identified thus far have 
an association with disease and could therefore become useful biomarkers to 
stratify disease risk, as well as possibly identifying novel drug targets in the 
near future. 
  

































































Membranous nephropathy (MN) is a kidney specific autoimmune disease with 
an incidence of ten per million per year (4). It is the leading cause of nephrotic 
syndrome in European adults and progresses to end-stage renal disease 
(ESRD) in 30-40% of cases (5). Unlike many other autoimmune disorders, 
males are more often affected. Approximately 25% of patients have a 
secondary form of MN, which is diagnosed when an alternative identifiable 
underlying clinical condition is present. For example systemic lupus 
erythematosus, malignancy, medication or viral infections (5). The remaining 
75% of patients have no apparent cause and are termed ‘primary’ or 
idiopathic membranous nephropathy (IMN) (6). IMN is caused by in situ 
binding of circulating antibodies to a podocytic antigen. The phospholipase A2 
receptor 1 and thrombospondin type-1 domain-containing 7a are the major 
target antigens involved in the pathogenesis of IMN (7,8). Sub-epithelial 
immunoglobulin rich deposits demonstrated by electron microscopy are 
pathognomonic in MN (9)(7), constituting a definitive phenotype. While IMN 
does not show simple Mendelian inheritance, the role of underlying genetic 
factors has been confirmed in recent studies. 
 
Discovery of autoantigens 
The first autoantigen described in a rare case of antenatal MN was neutral 
endopeptidase (NEP), in 2002 (10)(46). The gene encoding NEP is 
metallomembrane endopeptidase. Truncated mutations were discovered in 
maternal DNA so the mother did not express NEP protein. When foetal NEP 
(paternal protein) was encountered during pregnancy, anti-NEP antibodies 
developed (with no consequence to the mother) which crossed the placenta to 



































































The discovery of circulating antibodies to the autoantigen phospholipase A2 
receptor 1 (PLA2R1) revolutionised our understanding of IMN as an 
autoimmune disease (7)(48). With Western blots and mass spectrometry the 
antibody was detected in serum from 26 out of 37 patients (70%) (7)(48). This 
has been confirmed in subsequent studies and proven to be specific to IMN 
and implicated in disease progression and outcome (12,13)(25,49). 
Most recently, combined immunologic and proteomic approaches identified 
thrombospondin type-1 domain-containing 7A (THSD7A) as another target 
autoantigen in MN (8)(50). THSD7A antibodies are found in approximately 2-
3% of MN patients. THSD7A like PLA2R1 is a heavily glycosylated, multi-
domain transmembrane receptor located on the podocyte membrane. 
THSD7A resembles some of the PLA2R1 immunological characteristics and 
autoantibody findings correlate with glomerular staining of the antigen. It is not 
understood why autoantibodies develop however, in some THSD7A 
associated cases the development of antibodies may be linked to malignant 
tumours (14,15)(51,52). Interestingly, dual positivity to both PLA2R1 and 
THSD7A is extremely rare with only 2 cases identified on biopsy staining 
(16)(53). 
 
Familial clustering of Membranous Nephropathy 
Whilst all available data points towards a strong genetic component, IMN 
appears not to be inherited in a simple Mendelian fashion. In 1984 the first 
case of identical twins developing IMN was published (17), and to date 
sixteen families have been reported to have familial IMN (3,18,17,19–24), 
suggesting strong genetic contribution. However, several sets of monozygotic 
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progression of disease (17,22). This suggests an environmental contribution 
to disease, which is not yet well established. 
There is a strong male preponderance in IMN (25) unlike other autoimmune 
diseases (26). An X-linked recessive pattern of inheritance was suggested 
based on the clustering of disease between non-identical brothers (17–19,21). 
Autosomal inheritance was also apparent in other families with male-to-male 
transmission (20,24) and affected members of both genders (18,23). Further 
support for the theory of an underlying genetic mechanism was provided by 
two brothers with a rare syndromic form of IMN (19). These brothers had both 
IMN and deafness but no linked HLA alleles (19). To date the involvement of 
antibodies against phospholipase A2 receptor 1 (aPLA2R1ab) in cases of 
familial MN are unknown. 
Two studies of paediatric primary MN report much lower positivity for PLA2R1 
staining of immune complexes on biopsy at 6% and 45% compared to adult 
studies at 70-80% (27,28). As yet the genetic background to paediatric MN 
has not been confirmed. 
 
Concept of genome-wide association studies and confirmation of 
genetic association 
 
The biggest breakthrough in the contribution of genetic factors in IMN so far 
was with three genome-wide association studies (GWAS) published in 2011 
(3). GWAS works with the hypothesis that the phenotype is associated with 
variations in a subset of several genes. These variations will be demarked by 
haplotypes / alleles that display frequency differences in the cases and 
controls. GWAS examine all chromosomes and its simplest form compares 
allele frequencies of given variations in cases to allele frequencies of controls 
(basic allele test). GWAS most often use common single nucleotide 
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polymorphisms (SNP), which are defined by an allele frequency in a given 
population of > 5%. The tenet is that any given disease, as long as there is no 
heterogeneity, will show a difference in the frequency of genetic variation 
within disease-associated genomic regions in comparison to unaffected 
controls. Thus, SNPs utilized as genetic markers, identify a chromosomal 
location of interest associated with disease. If the phenotype is clearly 
described and unique then GWAS can be powerful for discovery of associated 
alleles even with few cases (29,30)(8,9). The first ever GWAS published in 
macular degeneration utilised 96 cases and 50 controls only (29)(8). Of all 
SNPs genotyped 105,980 were analysed and an intronic and common variant 
in the complement factor H gene that increased the likelihood of macular 
degeneration by a factor of 7.4 was discovered (29)(8). This is contrary to the 
opinion (misconception) often presented in public that GWAS always need 
thousands or tens of thousands of samples to be able to identify genetic 
causes. When a phenotype is complex (i.e. hypertension, kidney failure), then 
indeed many more samples are needed to be able to identify regions of 
interest, i.e. associated alleles. 
 
Genome-wide association studies in membranous nephropathy 
The GWAS published in 2011 investigated European populations with renal 
biopsy proven IMN (3).  Three independent GWAS were performed, using 75 
French European cases, 146 Dutch European cases and 335 British 
European cases. Despite the small number of cases even in the smallest 
cohort (French), a significant association in 3 SNPs in an HLA-DQA1 allele on 
chromosome 6 was found. The 146 Dutch cases demonstrated a significant 
allelic association of 191 SNPs in HLA-DQA1. Additionally, 6 SNPs located 
within the PLA2R1 gene on chromosome 2 were associated with IMN, the 
strongest being SNP rs4664308. Finally, the British study found a significant 



































































PLA2R1 allele. Combining then the three cohorts in a meta-analysis with a 
total case population of 556 further strengthened the association of IMN with 
20 SNPs in HLA-DQA1 and 13 SNPs in PLA2R1. The effect size of the risk 
SNPs was examined, even in a heterozygous state of the risk allele the odds 
ratio was increased in both HLA-DQA1 and PLA2R1. The strongest 
association was with the HLA-DQA1 region, (the most significantly associated 
SNP being rs2187668) (3). In a homozygous state of the HLA-DQA1 risk 
allele the odds ratio of IMN was 20.2 (3). The odds ratio in a homozygous 
state for  and in PLA2R1  was 4.2 (3). Combining these two risk alleles further 
increased the risk of IMN to an odds ratio of 78.5 (3). This association was 
very robust for such a modest cohort (31)(10), which is unusual for a GWAS 
(18)(11). Also, no association was found with immunoglobulin G chains that 




The SNP coverage of these initial GWAS is low compared to the coverage 
available with more modern technology, particularly of the HLA alleles 
(34,35)(14,15). To further assess the strength of the SNP associations that 
were found in the British study an imputation study was performed (36)(16). 
Imputation is a method to increase the statistical power of association studies 
and potentially identify additional associated alleles (37,38)(17,18). This 
technique is based on knowledge about short stretches of shared haplotypes 
to provide information and predict untyped alleles (39)(19). Imputation takes 
advantage of haplotype composition to match known SNPs to other SNPs that 
are in linkage disequilibrium with one another. In this way, it was possible to 
impute and examine 8.9 million SNPs in the British cohort. The strongest 







































































found as independent risk factors. The PLA2R1 signal was somewhat weaker 
and HLA-DQA1 somewhat stronger than originally described, with 
homozygous risk alleles at both loci the combined odds ratio was greater at 
79.4 (36)(16). In addition, imputation of classical HLA alleles was performed, 
with the DRB1*0301-DQA1*0501-DQB1*0201 haplotype showing the 
strongest association but providing little information beyond the lead SNP in 
HLA-DQA1. Sub-group analyses were undertaken and there was no 
significant gender specific genetic difference and no additional loci were found 
on the X chromosome (36)(16), which may have been unexpected given the 
unusual strong male preponderance in IMN, but statistical power for these 
analyses was limited. The HLA region was analysed in much more detail and 
this demonstrated a several hundred kilobase pair linkage disequilibrium 
around HLA-DQA1 as well as other HLA class II genes (36)(16). 
 
M-type phospholipase A2 receptor 1 
To investigate whether specific variants within the PLA2R1 gene are causing 
this previously mentioned strong genetic association, sequencing of the 30 
PLA2R1 coding exons was performed. This was also an ethnically 
homogenous group, all 95 affected patients were white Europeans and only 
45% had circulating antibodies against phospholipase A2 receptor 1 
(aPLA2R1ab) (40)(20). All exons and splice sites of PLA2R1 were sequenced 
by Sanger sequencing and all observed variants including rare variants (minor 
allele frequency <1%) were analysed. To our initial surprise, no rare genetic 
variants causing a conformational change in PLA2R1 structure were found. Of 
the variants found 6 were common and 3 in splice sites (exon-intron 
boundaries). One of these non-synonymous (causing amino acid alteration) 
common variants (i.e. M292V) encodes an amino acid located within CTLD1 




































































cys-rich domain and unlikely to have a contributory role in the pathogenesis of 
IMN (40,41)(20,21). One reason for the lack of exonic, i.e. coding, differences 
may be that the true causal variant(s) lie(s) in the regulatory, i.e. intergenic or 
intronic regions of the gene. For this to be examined, sequencing of the whole 
genomic region would need to be done. A second reason for the lack of 
significant results was that only 45% of the cohort had detectable aPLA2R1ab. 
The remaining patients were aPLA2R1ab negative, and we now know that the 
association is strongest in aPLA2R1ab positive patients.  
It is therefore most interesting to note that despite IMN being a rare disease 
the variants found in PLA2R1 were common. An explanation for this would be 
that the common variants recognised together create a rare haplotype 
(40)(20). Additionally, an interaction between the PLA2R1 variants and the 
HLA-DQA1 haplotype in individuals predisposed to developing IMN might be 
infrequent in causing autoimmunity and may therefore account for the rarity of 
disease and suggest a mechanism for how IMN develops (42)(22). 
Genotyping of hundreds of thousands of individuals will provide an answer to 
whether there is a unique genetic fingerprint of individuals developing IMN 
and what proportion of individuals having this genetic fingerprint actually 
present with IMN (i.e. show penetrance). 
 
Antibody and gene interplay 
 
The presence of circulating antibodies against PLA2R1 and THSD7A is 
variable between patients and throughout the different stages of disease (43). 
During active nephrosis and disease these levels tend to be high and 
remission is predated by reducing antibody titres (43). Serologically antibody 
negative MN patients may have glomerular PLA2R1 positivity (12). The 
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is the same and they represent a spectrum of the same disease. A hypothesis 
is these patients have the same genetic PLA2R1 risk variants yet are 
demonstrating incomplete penetrance of disease manifestation. Studies were 
undertaken to elucidate the association of genetic variants and circulating 
antibodies as the antibody titres have been associated with severity of 
disease and long term outcome (13).  
PLA2R1 risk alleles are positively correlated with positivity of the pathogenic 
aPLA2R1ab (44)(23). When patients were divided into low- or high-risk 
PLA2R1 genotypes, only 4% of those with the low-risk genotype had 
detectable aPLA2R1ab compared to 76% of those with the high-risk genotype 
(44)(23). This association was further strengthened for the detection of 
aPLA2R1ab after combination with the low- or high-risk HLA-DQA1 genotypes 
with 0% versus 73% respectively (44)(23). A larger study compared 
aPLA2R1ab glomerular PLA2R1 antibody staining (positivity)e to negative 
patients and found the PLA2R1 association only in patients with aPLA2R1ab 
positivity. In aPLA2R1ab negative patients compared to controls there was no 
association with PLA2R1 SNPs (45)(24). 
This is relevant as increased aPLA2R1ab correlates with clinical progression 
of disease; with higher titres associated with ESRD at five years and lower 
rates of spontaneous remission (13)(25). In an Indian cohort, however, there 
was no significant association between aPLA2R1ab status and PLA2R1 
SNPs. Instead there was an association of the HLA-DQA1 risk allele with 
aPLA2R1ab positivity (46)(26). This was subsequently replicated in a 
European cohort and the presence of the risk alleles in either a heterozygous 
or homozygous state in HLA-DQA1 and -DQB1 was significantly associated 
with higher circulating aPLA2R1ab (13)(25). Neither the SNPs in intron 1 or 
exon 5 in HLA-DQA1 alone had an effect on aPLA2R1ab titres (13)(25). A 
Two recent Chinese study studies demonstrated the strong HLA association 
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with  aPLA2R1ab positivity (47,48). One had an association with HLA-DQB1 
DRB1 and the other HLA-DRB3 both of which share a haplotype so may 
represent a common mechanism in Chinese patients (47–49)having a strong 
association with aPLA2R1ab positivity (27).. The risk alleles in PLA2R1 are 
said to be present in patients with systemic lupus erythematosus (SMN) albeit 
with lower odds ratios (50)(28) and aPLA2R1ab are occasionally found in 
patients with SMN (51)(29). 
 
Ethnic differences 
Our findings from the first IMN GWAS (3) have been replicated in other 
studies, however different techniques have been used. These studies used a 
candidate gene approach whereby a specific variant alone is genotyped (52). 
These SNPs are chosen as the candidate gene based on prior knowledge 
about PLA2R1 or previously described SNPs (52,53). This is a major limitation 
of the candidate gene approach; they can only confirm or refute an 
association with a variant and cannot detect new associations (52,53). 
Another limitation is findings are often not replicated in subsequent 
independent studies rendering the results potentially unreliable (52,53). Table 
1 provides a summary of genotyping studies to date in MN. 
In MN, tThe first of study utilising the candidate gene approach se was in a 
small Spanish cohort of 89 patients, where only a single SNP in both the HLA-
DQA1 and PLA2R1 genes was investigated (54)(30). This study too found the 
same association in both alleles in their cohort, with an added effect of 
homozygous risk alleles in both genes increasing the odds ratio of IMN to 7.3 
(54)(30). As these studies were performed in European populations it was of 
interest to investigate if these associations held true in other ethnicities. 
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In a cohort of 114 Indian patients the same risk alleles were identified as by 
Stanescu et al. (46)(26). The strongest association was with the homozygous 
genotype in the HLA-DQA1 SNP rs2187668. Three SNPs were associated 
within PLA2R1, one of which was the same SNP described in the GWAS (3), 
rs4664308 with the AA risk genotype (46)(26). The risk of IMN was increased 
by 58.4 with all four risk alleles in HLA-DQA1 and PLA2R1 (46)(26). This is a 
strong association with a small sample size.  
The only study undertaken in African-Americans so far examined 243 African-
American and 467 European cases of IMN (45)(24). Targeted sequencing of 
candidate genes using conventional polymerase chain reaction was 
performed, with genotyping of 6 PLA2R1 SNPs and a single SNP in the HLA-
DQA1 region (45)(24). Further, they differentiated between patients who had 
PLA2R1 positivity on renal biopsy (using immunofluorescence) detectable 
antibodies (aPLA2R1ab) (115 African-American cases) and those who did not 
(128 African-American cases) (45)(24). No association was found in African-
Americans with the HLA-DQA1 SNP rs2187668, suggesting that this SNP is 
tagging the causal variant(s) in individuals of European and East Asian 
ancestry but not in African Americans. In the European sub-group analysis 
however, the strong association was present with HLA-DQA1 (45)(24). 
Further the PLA2R1 signal was associated with glomerular aPLA2R1ab 
positivitye patients in the African-American cohort but not in aPLA2R1ab 
negative patients (45)(24). The strength of this association was lower than 
that found in Europeans, with the strongest association in Europeans with 
detectable aPLA2R1ab (45)(24).  
Chinese patients demonstrated a similar association with PLA2R1 risk alleles 
increasing the risk of IMN but without any effect on outcomes and response to 
treatment (55)(31). Liu et al. analysed 2 SNPs in 129 Chinese IMN patients 













































































difference in the different genotypes relating to progression to ESRD, though 
the patient numbers were too small to identify such a difference. A 
heterozygous state for the risk allele in the exonic PLA2R1 region conferred a 
lower success rate of achieving remission (55)(31). A larger study including 
1112 Chinese patients with IMN genotyped 3 SNPs in PLA2R1 and 3 SNPs in 
HLA genes and found that both were associated with IMN (44)(23). 
Interestingly, in the Chinese population the association with HLA-DQA1 was 
lower than in Europeans, and there was no association with HLA Class II 
alleles apart from HLA-DOB or -DQB2 (44)(23). A study of 261 IMN Chinese 
patients has linked HLA-DRB1*1501 most significantly with IMN (47)(27). 
After correction for HLA-DRB1*0301, the HLA-DQA1 association was 
diminished as these two loci are in strong linkage disequilibrium with one 
another (47)(27). The additive effect of homozygous risk alleles in HLA-DQA1 
and PLA2R1 increased the odds ratio of IMN to 11.13 which is considerably 
lower than that found in the European studies (3,44)(3,23). However, with the 
newly discovered association of HLA-DRB1 and PLA2R1 the odds ratio is 
considerably higher at 32.4 in the Chinese population (47)(27). Another 
Chinese study in patients phenotyped by PLA2R1 positivity demonstrated a 
stronger association with HLA-DRB3*0202 and HLA-DRB1*1501 with odds 
ratios of 24.9 and 17.7 respectively (48). Both studies have identified the 
same allele in HLA-DRB1*1501 which may truly represent the causative allele 
in Chinese patients. Difficulties arise with analysis of such data as the allele 
frequencies vary between ethnic groups (56)(32). The Chinese are genetically 
heterogeneous and within a control population there were different minor 
allele frequencies in HLA-DQA1 and PLA2R1 dependent on their 
geographical location (56)(32).  
A study of 4 SNPs in PLA2R1 in 199 Korean patients also confirmed an 
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Stanescu et al. SNPs (3,57)(3,33). Patients with SMN had the same genotype 
as controls (57)(33). 
Finally, a Japanese study performed genotyping of 15 SNPs in the PLA2R1 
gene and 6 HLA genes - A, B, C, DRB1, DQB1 and DPB1 (58)(34). The 
discovery sample had 53 patients, and the replication study 130 (58)(34). 
After corrections for multiple testing and correlation in the replication study 4 
SNPs in PLA2R1 were associated with IMN, 2 of which were intronic (58)(34). 
None of the class I HLA genes (A, B or C) were significantly associated with 
IMN, however HLA-DRB1*15:01 was the most strongly associated with an 
odds ratio of 2.85 followed by HLA-DQB1, odds ratio 2.6. These odd ratios 
increased in the replication study and then subsequently in the combined 
analysis to 3.09 and 3.1 respectively (58)(34). Interactions between the HLA 
and PLA2R1 homozygous risk alleles further increased the risk of developing 
IMN, with the largest odds ratio of 17.53 in the HLA-DRB1*15:01 – 
DQB1*06:02 and rs2715928 PLA2R1 combination. Whilst these interactions 
are statistically significant they are still considerably lower than the strength of 
interactions found in the European GWAS (3). The differences may be due to 
sample size differences or because HLA-DQA1, which is a larger contributor 
to the cumulative risk in the European study, was not genotyped in this 
Japanese study, or because of differences in linkage disequilibrium with the 
causal variant across different ethnic groups. 
 
Functional effect of genes 
The underlying genetic risk alleles that have been identified to date are 
different between individual studies but universally there is an association of 
IMN with the human genes encoding leucocyte class II antigens and PLA2R1. 






































































for disease development are required. It is also possible that the previously 
identified risk alleles do not affect disease onset but instead disease severity 
(42)(22).  
It is unclear how the genetic risk alleles of class II HLA (e.g. DQA1) and 
PLA2R are translated through the pathophysiological disease mechanism, but 
antigen presentation to T cells to initiate T cell help for aPLA2R1ab production 
is one possibility. These risk alleles encode protein receptors which interact 
during antigen presentation to stimulate T cells. In this situation, PLA2R1 
protein, processed in macrophage/dendritic cells is displayed on the cell 
surface as PLA2R1 peptides bound to the class II receptor (DQA1) groove. 
The genetics of DQA1 will shape the amino acid structure of its receptor 
groove thus defining and restricting the possible 15mer peptide sequences 
available from PLA2R1 that will fit the groove. The genetics of PLA2R1 may 
control the possible enzyme fragmentation pattern of PLA2R1 by: 
a) change in amino acid either creating or destroying an enzyme cut site 
b) change in splice sites controlling the protein species available for 
fragmentation 
c) level of transcript leading to higher levels of peptide 
As yet these T cell peptides (the PLA2R1 peptides presented on DQA1) have 
not been described experimentally but studies are in progress. A recent study 
has predicted possible T cell epitopes in PLA2R1 and attempted to model the 
interaction with known class II risk alleles (47)(27). It is important to 
emphasise that DQA1 may not be the causal allele, particularly in non-
European ethnicities (47,48).  
To elucidate the HLA causal alleles further larger multi-ethnic GWAS 
combined with larger-scale HLA sequencing and fine-mapping studies are 
necessary. It is vital to do this before modelling their functional effects 
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however, Iit would be useful to have further transcriptomic and proteomic 
studies to ascertain if PLA2R expression is modified and if this is due to an 




A comparison of 23 spontaneously remitting to 55 non-remitting IMN patients 
found no difference in genetic variants in HLA-DQA1 or PLA2R1 (54)(30). In 
contrast, Liu et al. reported an association between lower rates of remission 
after treatment and the PLA2R1 SNPs rs6757188 (CT genotype) and 
rs35771982 (CG genotype) (55)(31).  
 
Response to treatment 
Patients with the risk genotypes in HLA-DQA1 and PLA2R1 respond to 
immunosuppression, though the odds ratio is low at only 0.12 (54)(30). The 
total number of patients assessed was small with 27 responders and 28 non-
responders (54)(30). After adjustment for baseline proteinuria the predictive 
value of risk genotype increased (54)(30). Analysis of 2 different PLA2R1 
SNPs revealed no difference between the outcomes of patients treated either 
conservatively or with immunosuppression (55)(31).  
 
Decline in renal function 
The high risk alleles (AA genotype) in HLA-DQA1, despite being strongly 
associated with IMN, are potentially protective against declining renal function 
(54)(30). High risk genotype patients had a longer time to doubling of their 
serum creatinine of 16.3 years compared to 13 years, though this was a small 
subgroup of only 83 patients (54)(30). No association was found in the 8 
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Japanese patients that had a 50% increase in their serum creatinine with 
HLA-DRB1 and -DQB1 over an 11 year period, nor with patient survival 
(58)(34). The association with PLA2R1 risk alleles and declining renal function 
has been investigated in different ethnicities and no association was found 
(54,57)(30,33). In addition there was no association with ESRD or death 
(55)(31).  
As yet there has been no conclusive evidence associating genetic variants to 
remission status, response to treatment or a decline in renal function. These 
factors are difficult to determine as studies are often done in retrospective 
cohorts where confounders such as immunosuppression or disease severity 
have a significant effect on the outcomes. Decline in renal function is 
multifactorial and is related to blood pressure control, severity of proteinuria, 
renal function at disease onset, age and gender amongst others. These 
factors themselves are likely to be independent risk factors which is why 
studies to date have not been significant. It may be argued that these factors 
are caused or influenced by genetics thereby further complicating the 
potential genetic risk profile with IMN.  
 
Familial clustering of Membranous Nephropathy 
Whilst all available data points towards a strong genetic component, IMN 
appears not to be inherited in a simple Mendelian fashion which is supported 
by the discovery of at least two genetic risk loci so far. In 1984 the first case of 
identical twins developing IMN was published (35), and to date sixteen 
families have been reported to have familial IMN (3,11,35–41), suggesting 
strong genetic contribution. However, several sets of monozygotic twins with 



































































disease (35,39). This suggests an environmental contribution to disease, 
which is not yet well established. 
There is a strong male preponderance in IMN (42) unlike other autoimmune 
diseases (43). An X-linked recessive pattern of inheritance was suggested 
based on the clustering of disease between non-identical brothers 
(11,35,36,38). Autosomal inheritance was also apparent in other families with 
male-to-male transmission (37,41) and affected members of both genders 
(11,40). Further support for the theory of an underlying genetic mechanism 
was provided by two brothers with a rare syndromic form of IMN (36). These 
brothers had both IMN and deafness but no linked HLA alleles (36). To date 
the involvement of aPLA2R1ab in cases of familial MN in unknown. 
Two studies of paediatric primary MN report much lower positivity for PLA2R1 
staining of immune complexes on biopsy at 6% and 45% compared to adult 
studies at 70-80% (44,45). As yet the genetic background to paediatric MN 
has not been confirmed. 
 
Discovery of autoantigens 
The first autoantigen described in a rare case of antenatal MN was neutral 
endopeptidase (NEP), in 2002 (46). The gene encoding NEP is 
metallomembrane endopeptidase. Truncated mutations were discovered in 
maternal DNA so the mother did not express NEP protein. When foetal NEP 
(paternal protein) was encountered during pregnancy, anti-NEP antibodies 
developed (with no consequence to the mother) which crossed the placenta to 
cause neonatal MN (46,47).  
The discovery of circulating antibodies to the autoantigen PLA2R1 
revolutionised our understanding of IMN as an autoimmune disease (48). With 































































Western blots and mass spectrometry the antibody was detected in serum 
from 26 out of 37 patients (70%) (48). This has been confirmed in subsequent 
studies and proven to be specific to IMN and implicated in disease 
progression and outcome (25,49). 
Most recently, combined immunologic and proteomic approaches identified 
thrombospondin type-1 domain-containing 7A (THSD7A) as another target 
autoantigen in MN (50). THSD7A antibodies are found in approximately 2-3% 
of MN patients. THSD7A like PLA2R1 is a heavily glycosylated, multi-domain 
transmembrane receptor located on the podocyte membrane. THSD7A 
resembles some of the PLA2R1 immunological characteristics and 
autoantibody findings correlate with glomerular staining of the antigen. It is not 
understood why autoantibodies develop however, in some THSD7A 
associated cases the development of antibodies may be linked to malignant 
tumours (51,52). Interestingly, dual positivity to both PLA2R1 and THSD7A is 
extremely rare with only 2 cases identified on biopsy staining (53). 
 
Conclusion 
There has been an exponential increase in our understanding of IMN since 
2009, when PLA2R1 was identified as the most significant pathogenic 
autoantigen in IMN. IMN therefore may occur when three independent risk 
factors combine: unique polymorphisms in PLA2R1, the HLA-DQA1 region 
and environmental factors. There are ethnic specific differences in these 
alleles and the potential that risk alleles may contribute in predicting disease 
outcomes. The complex pathomechanisms of disease development highlight 
some of the potential problems in analysing and predicting the risk for disease 
progression. The genetic variants may alter the expression or function of the 
target antigens and enable autoantibody formation. While no rare variants (i.e. 































































mutations) were found in the coding region of PLA2R1 the role of intronic 
variants needs to be investigated given their large regulatory role. As shown 
before, non-coding SNPs (i.e. intergenic or intronic genetic variations) are 
associated with ESRD (59)(54) and other autoimmune conditions (60)(55).  
Whole genome sequencing is becoming more affordable and faster and may 
help illuminate the true role of intergenic and intronic genetic variants in IMN. 
The genomic studies could be augmented with epigenomic, transcriptomic 
and proteomic studies to ascertain the functional effect of gene variants. The 
regulatory regions that control autoantibody production such as transcription 
factors or micro RNA could be altered by the identified risk SNPs in a 
mechanism analogous to psoriasis (31)(10). If upstream and downstream 
regulatory region variants were found these would be potential therapeutic 
drug targets, possibly preventing the deleterious effects of current 
immunotherapy. Given the large odds ratio with joint homozygosity, 
genotyping could be utilised to stratify disease risk and outcomes. The utility 
of genetic profiling in IMN could prove to be vital for non-invasive screening or 
risk stratification (18,31)(10,11). The tools (aPLA2R1ab) available to us are of 
assistance but by understanding the genetics we may be able to explain why 
the autoantibodies develop in the first instance (18)(11). Current studies have 
been limited by small sample size and so there may be a lack of appreciation 
of potential other associations. Expanding the horizons further, there may 
even be a role for ascertaining epidemiologic risk for IMN with risk alleles and 
seeing if people in the general population have a genetic predisposition to 
disease (18)(11). There may be an indirect interaction between genetics and 
disease, such as molecular mimicry whereby a microbe or environmental 
antigen resembles a PLA2R1 variant and causes autoimmunity in patients 
carrying the HLA-DQA1 risk alleles (42)(22). The reported homology of part of 







































































enzyme illustrates how antibodies raised during infection may potentially 
cross react with an autoantigen (41)(21). Normal control populations without 
IMN but with the risk alleles will be the most useful in identifying the triggers or 
environmental factors that contribute to eventual disease acquisition which 
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1. Although the focus of this review is on the genetics of 
membranous nephropathy, I feel that the ‘Discovery of autoantigens’ section 
(pp. 14-15) would be better placed at the start of the manuscript, so that the 
reader has a better idea of how the PLA2R1 genetic locus fits in to the 
overall understanding of the disease. At the very least, the original articles 
reporting the identification of the two autoantigens, PLA2R and THSD7A, 
should be cited in the Introduction where they are first mentioned. 
 
Thank you, these are very helpful comments and the manuscript has been 
revised to change the order of the paragraphs. The discovery of 
autoantigens now comes after the introduction. Further the references 
have been added to the introduction as you correctly mention where we 
first introduced the concepts of the antigens and antibodies. 
 
2. I would also like to see a better discussion about the variable presence of 
circulating antibodies, perhaps as an introductory paragraph in the 
‘Antibodies and gene interplay’ section (p. 7). In some ways, the phenotype 
of seropositivity for anti-PLA2R could be considered in genetic terms as one 
of incomplete penetrance, since individuals may not always exhibit clinical 
disease or circulating autoantibodies, despite having PLA2R-associated MN 
as defined by prior episodes of seropositivity, or the presence of PLA2R 
tissue positivity on biopsy. The relationship between genetics, the presence 
of circulating antibodies, clinical parameters such as proteinuria, and longer-
term outcomes is not immediately obvious in this review, and should 
be clarified as above.  
 
We have added in an introductory paragraph in the ‘Antibody and gene 
interplay’ section as suggested. The relationship between genetics and 
circulating antibodies is certainly known but the clinical parameters are 
more associated with the antibody levels which we also discuss within the 
same section paragraph 3. For the association of the genetics and clinical 
parameters please see the ‘functional effect of genes’ section now on page 
14. 
 
3. The sections describing the associations between genetic variants and 
‘Remission status’ (p. 12), ‘Response to treatment’ (p. 13), and ‘Decline in 
renal function’ (p. 13) leave out any mention of other factors (spontaneous 
remission, immunosuppressive treatment, duration and severity of 
proteinuria, etc) that may have more important effects on these outcomes 
than do the genetic variants. Such a discussion might explain to the reader 
why these associations with the genetic variants are not significant. 
 
































































We have adjusted the manuscript to include a new paragraph stating some 
of the other factors that may act independently to affect the outcomes of 
disease in MN, see page 16 under the ‘decline in renal function’ heading. 
 
4.  Please rephrase the sentence on p. 5: ‘In a homozygous state of the HLA-
DQA1 risk allele the odds ratio of IMN was 20.2 and in PLA2R1 4.2.’ It is not 
immediately clearly that the latter odds ratio refers to the risk of IMN in those 
individuals homozygous for the PLA2R1 risk allele. 
 
Apologies for this confusion, we have adjusted the manuscript to clarify 
this point further that it is indeed also a homozygous state of the PLA2R1 
allele.  
 
5. In the ‘Ethnic differences’ section (p. 8), in keeping with trying to explain 
basic concepts for those readers uninitiated in the techniques of genetic 
analysis, I would suggest better explaining the candidate gene approach. In 
these earlier studies, the investigators focused on SNPs in/near the PLA2R1 
gene because of its recent identification of the protein product PLA2R as an 
autoantigen, or focused on the same SNPs in PLA2R1 or HLA-DQA1 that 
had been identified in the Stanescu et al. 2011 NEJM paper. The limitations 
of the candidate gene approach for discovering new associations should be 
explained, and that they are rather confirmatory (or not) in these different 
ethnic and geographic cohorts. 
 
We have integrated and expanded on the candidate gene approach as 
suggested to reflect and demonstrate this point to readers, thank you for 
this helpful suggestion. 
 
6. In the same section (p. 9), please check reference 24 (Saeed et al.) to 
confirm whether those authors stratified their patients based 
on autoantibody positivity for anti-PLA2R, or rather tissue positivity for the 
PLA2R antigen (the reference is not available to me online). 
 
Saeed et al. stratified their patients by PLA2R immunofluorescence on 
renal biopsy. The manuscript has been edited to reflect this and highlight 






































































7. To improve the flow of the manuscript, I would suggest moving the sections 
on the familial clustering and auto-antigen detection to the front of the 
manuscript, after introduction but before discussing GWAS findings and 
replication studies. It is important to describe familial clustering before 
describing various genetic approaches. 
 
Thank you for this suggestion which is like reviewer 1 with regards to the 
ordering of the paragraphs. We have edited the manuscript to reflect this. 
 
8. It may be helpful to tabulate the results of all replication studies of PLA2R1 
and HLA associations published to date, including sample sizes, ethnicities, 
allelic frequencies and effect estimates for these two loci. 
 
We have added table 1 with the relevant summary of all the studies done to 
date as requested.  
 
9. There is some discussion of the DQA1 binding groove (in the “Functional 
Effects” section), however, recent sequencing studies suggest that HLA-
DQA1 may not be the causal gene. I would recommend discussing the 
results of these two studies in more depth, especially the association with 
DRB1*15:01 in Chinese (Cui et al. JASN 2017; Le at al. JASN 2017). I 
would emphasize again that larger-scale sequencing and fine-mapping 
studies to define causal alleles within the HLA region are  
still needed in Europeans before one can model their functional effects. 
 
We have edited the manuscript in the ethical differences section starting 
page 13 to include more in depth information about these studies. Further 
in the functional effects section we have generalised the statements to 
reflect the differences in class II HLA types in diff rent ethnicities.  
 
10. Page 6: “(after imputation) the PLA2R signal was somewhat weaker”. I am 
not clear why the imputation would weaken an association signal 
that originates from a genotyped SNP. Presumably the same genotyped 
SNP that gives the original signal should have very similar association 
signal after imputation (this is a very minor point, but would be nice to 
clarify). 
 
Imputation compares more SNPs than the original GWAS so when applying 
the Bonferroni correction it is possible that previous associations become 
weaker than they previously were. In addition, and here most relevant, the 
associations and their significances are relating to a different number of 
controls which can indeed change significance levels. 
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